BJOG An International Journal of Obstetrics & Gynaecology · 1997 · 144 citations · 11 references
MedicineMaternal HealthObstetricsMaternal-fetal MedicineObstetric HemorrhagePostpartum Hemorrhage ManagementBlood Loss AssessmentIntrapartum HemorrhageObstetric Hemorrhage ManagementPostpartum HemorrhageQuantification Of Blood LossUterotonic TherapyComparative Effectiveness Of UterotonicsEffectiveness In Postpartum HemorrhageIntramuscular OxytocinIntravenous OxytocinMaternal OxytocinOxytocin UseTreatment Of Postpartum HemorrhageVaginal Delivery Rates
OBJECTIVE: To compare intravenous oxytocin administration (Partocon 10 IU) with saline solution in the management of postpartum haemorrhage in the third stage of labour. DESIGN: A double-blind, randomised controlled trial involving 1000 parturients with singleton fetuses in cephalic presentation and undergoing vaginal delivery, randomly allocated to treatment with oxytocin (n = 513) or 0.9% saline solution (n = 487). SETTING: Labour ward at a central county hospital. MAIN OUTCOME MEASURES: Mean blood loss (total, and before and after placenta delivery); frequencies of blood loss > 800 mL, need of additional oxytocic treatment, postpartum haemoglobin < 10 g/dL; and duration of postpartum hospitalisation. RESULTS: As compared with saline solution, oxytocin administration was associated with significant reduction in mean total blood loss (407 versus 527 mL), and in frequencies of postpartum haemorrhage > 800 mL (8.8% versus 5.2%), additional treatment with metylergometrine (7.8% versus 13.8%), and postpartum Hb < 10 g/dL (9.7% versus 15.2%), and a nonsignificant increase in the frequency of manual placenta removal (3.5% versus 2.3%). There was no group difference in the mean duration of postpartum hospitalisation (4.6 versus 4.5 days, respectively). CONCLUSIONS: Administration of intravenous oxytocin in the third stage of labour is associated with an approximately 22% reduction in mean blood loss, and approximately 40% reductions in frequencies of postpartum haemorrhage (> 500 mL or > 800 mL) and of postpartum haemoglobin < 10 g/dL. Identification of risk groups for oxytocin treatment does not seem worthwhile. Oxytocin is a cheap atoxic drug and should be given routinely after vaginal delivery.
11
The history and present-day use of ergot.
Moir Jc · PubMed · 1955 · 391 citations · Full text
Humanities, History, Ergonomics +2
CONFOUNDING AND EFFECT-MODIFICATION
Olli S. Miettinen · American Journal of Epidemiology · 1974 · 359 citations
The number needed to treat: a clinically useful nomogram in its proper context
Gilles Châtellier, Éric Zapletal, D Lemaitre et al. · BMJ · 1996 · 204 citations
THE SUBSTANCE RESPONSIBLE FOR THE TRADITIONAL CLINICAL EFFECT OF ERGOT
Harold Ward Dudley, Chassar Moir · BMJ · 1935 · 114 citations · Full text